Corcept Therapeutics Incorporated (NASDAQ: CORT) reported that patients with amyotrophic lateral sclerosis who received its experimental drug dazucorilant showed an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA